Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of a Single Dose of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia

Next Previous
Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of a Single Dose of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimagrumab (Primary)
  • Indications Cachexia; Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 10 Aug 2018 Results (n=67) published in the American Journal of Respiratory and Critical Care Medicine.
  • 18 May 2016 Primary endpoint has been met. (Change in thigh muscle volume compare to placebo as measured by MRI), as per an abstract presented at the 112th International Conference of the American Thoracic Society.
  • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top